RECRUITING

Institut Paoli Calmettes Ovarian Cancer Database

NCT02869568•Institut Paoli-Calmettes

View on ClinicalTrials.gov

Summary

Database of Institut Paoli-Calmettes patients diagnosed with ovarian cancer

Eligibility

Age

18 - 95 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Patient with a diagnosis of ovarian cancer

Exclusion Criteria

•Diagnosis of fallopian tube cancer

Locations (1)

Institut Paoli-Calmettes

Marseille, Bouches-du Rhône, France

Key Dates

Start Date

January 1, 2000

Primary Completion Date

January 1, 2030

Completion Date

December 1, 2030

Last Updated

August 17, 2016

Enrollment

6,000

ESTIMATED participants

Conditions

Ovarian Neoplasms

Interventions

Data collection

OTHER

Contacts

Dominique Genre, MD

CONTACT

0033491223778 drci.up@ipc.unicancer.fr

Lilian Laborde

CONTACT

0033491223778 labordel@ipc.unicancer.fr

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE1